DOCSLIB.ORG

Cd79a PE Also Known As: Mb-1 Catalog Number(S): 9012-0792-025 (25 Tests), 9012-0792-120 (120 Tests)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cd79a PE Also Known As: Mb-1 Catalog Number(S): 9012-0792-025 (25 Tests), 9012-0792-120 (120 Tests) Page 1 of 2 CD79a PE Also Known As: mb-1 Catalog Number(s): 9012-0792-025 (25 tests), 9012-0792-120 (120 tests) Fluorescence profiles of normal human peripheral blood lymphocytes unstained (blue histogram) or stained intracellularly with CD79a PE (purple histogram). Product Information Contents: CD79a PE Storage Conditions: Store at 2-8°C. Catalog Number(s): 9012-0792-025 (25 tests), Do not freeze. 9012-0792-120 (120 tests) Light-sensitive material. Clone: HM47 Caution, contains Azide Concentration: 5 uL (0.06 ug)/test (a test is Manufacturer: eBioscience, Inc., 10255 defined as the amount that will stain Science Center Drive, San Diego, CA 92121, 1 x 10e6 cells in 100 uL) USA Host/Isotype: Mouse IgG1, kappa Authorized Representative: Bender HLDA Workshop: V MedSystems GmbH, an eBioscience Company Formulation: Aqueous buffer, 0.09% sodium Campus Vienna Biocenter 2 A-1030 Vienna azide, may contain carrier protein/stabilizer. Austria Intended Use Using this flow cytometric analysis protocol, one can The HM47 fluorochrome-conjugated monoclonal perform a simultaneous analysis of surface molecules antibody reacts with the human CD79a antigen. CD79a at the single-cell level. can be detected in human biological samples using Description immunological techniques. The monoclonal antibody HM47 recognizes the Principles of the Test cytoplasmic domain of CD79a, also known as mb-1. Flow cytometry is a useful tool for simultaneously CD79a is a 47 kDa membrane glycoprotein that measuring multiple physical properties of individual associates with CD79b to form the heterodimeric B cell particles (such as cells). Cells pass single-file through receptor (BCR). This receptor is responsible for B cell a laser beam. As each cell passes through the laser signaling, resulting in activation, apoptosis or anergy. beam, the cytometer records how the cell or particle Expression of CD79a is found throughout development scatters incident laser light and emits fluorescence. from the earliest pre-B cell to plasma cells. CD79 is Document # 31138_01_en • Effective date: 12/16/2011 Not for further distribution without written consent. Copyright © 2000-2010 eBioscience, Inc. www.eBioscience.com ORDER INQUIRIES • +43 1 796 40 40-120 TECH • +43 1 796 40 40-0 [email protected] Page 2 of 2 expressed on B cell neoplasms and some non-B cell 5. Incubate samples in the dark at room temperature malignancies such as AML. Unlike other antibodies for 10 minutes. Do not exceed 15 minutes of that can be masked in B cell neoplastic cells, HM47 is incubation with the RBC Lysis Buffer. a reliable antibody for recognizing CD79a and, as such, 6. Centrifuge samples at 300-400 x g for 5 minutes is a good marker for B cells. at room temperature, decant/aspirate supernatant Specimen Collection and Storage Instructions and wash 1 time with 2 ml of Flow Cytometry Collect venous blood sample by venipuncture into a Staining Buffer. sterile blood collection tube using an appropriate 7. Centrifuge samples at 300-400 x g for 5 minutes anticoagulant (EDTA is recommended). Keep samples at room temperature, decant/aspirate supernatant. at room temperature (18-25°C). Prior to use, mix 8. Resuspend stained cell pellet in 1 mL Flow Cytometry samples by gentle agitation. Staining Buffer and analyze samples on a flow cytometer. Materials Required But Not Provided 12x75 mm test tubes Limitations Buffers (eBioscience Flow Cytometry Staining 1. For optimal performance of fluorochrome Buffer, Cat. No. 00-4222 recommended) conjugated antibodies, store vials at 2-8°C in the Lysis Buffer (eBioscience 1X RBC Lysis Buffer, dark. Do not freeze. Cat. No. 00-4333 or eBioscience 1-step Fix/Lyse 2. Centrifuge the antibody vial prior to opening to Solution (10X), Cat. No. 00-5333 recommended) recover the maximum volume. For intracellular staining use IC Fixation Buffer 3. Except where noted in the protocol, all staining and Permeabilization Buffer, Cat. No. 88-8823 should be done on ice or at 2-8°C with minimal (intracellular cytokine or cytoplasmic protein exposure to light. staining) or Foxp3 Buffer Set, Cat. No. 00-5523 Performance Characteristics (For nuclear protein staining). Refer to the Best Consistency of high-quality reagents is ensured by Protocols section of the eBioscience website for testing each lot of monoclonal antibody for the "Staining Intracellular Antigens for Flow conformance against characteristics of a standard Cytometry" protocols. reagent. Representative flow cytometric data is Viability stain (7-AAD Viability Staining Solution , included where appropriate. Cat. No. 00-6993 or Propidium Iodide Staining Evidence of Deterioration Solution, Cat. No. 00-6990 recommended) For questions or concerns regarding the performance Automated pipettes or quality of products received, please contact Centrifuge eBioscience Technical Support (see below). Vortex mixer References Ice bucket or refrigerator Procedures for the Collection of Diagnostic Blood Flow cytometer Specimens by Venipuncture (H3-A6), 3rd Edition Test Protocol published by the National Committee for Clinical NOTE: For intracellular staining, refer to the Best Laboratory Standards. Protocols section of the eBioscience website for the Schlossman SF, Boumsell L, Gilks W, et al, eds. Leucocyte "Staining Intracellular Antigens for Flow Cytometry" Typing V: White Cell Differentiation Antigens. Oxford protocols. University Press. New York. 1995. 1. Aliquot 100 µL of the test sample into tubes. Sakaguchi N, et al. B lymphocyte lineage-restricted 2. Add 5 µL of the appropriate antibody to each tube. expression of mb-1, a gene with CD3-like structural 3. Incubate 30-60 minutes at 2-8°C. Alternatively, properties. EMBO J. 1988;7:3457-3464. samples can be incubated at room temperature in the dark 15-30 minutes. 4. Add 2 ml of 1X RBC Lysis Buffer (at room temperature) per tube. Mix gently. (Alternatively, samples can be incubated with 2 mL 1-step Fix/Lyse Solution.) Document # 31138_01_en • Effective date: 12/16/2011 Not for further distribution without written consent. Copyright © 2000-2010 eBioscience, Inc. www.eBioscience.com ORDER INQUIRIES • +43 1 796 40 40-120 TECH • +43 1 796 40 40-0 [email protected] .
Load more

Recommended publications
  • Molecules with Specificity for Cd45 and Cd79 Moleküle Mit Cd45- Und Cd79-Spezifizität Molécules Présentant Une Spécificité Vis-À-Vis De Cd45 Et Cd79
    (19) *EP003169704B1* (11) EP 3 169 704 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 16/28 (2006.01) 29.07.2020 Bulletin 2020/31 (86) International application number: (21) Application number: 15738655.8 PCT/EP2015/066368 (22) Date of filing: 16.07.2015 (87) International publication number: WO 2016/009029 (21.01.2016 Gazette 2016/03) (54) MOLECULES WITH SPECIFICITY FOR CD45 AND CD79 MOLEKÜLE MIT CD45- UND CD79-SPEZIFIZITÄT MOLÉCULES PRÉSENTANT UNE SPÉCIFICITÉ VIS-À-VIS DE CD45 ET CD79 (84) Designated Contracting States: • WRIGHT, Michael John AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Slough GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Berkshire SL1 3WE (GB) PL PT RO RS SE SI SK SM TR • TYSON, Kerry Designated Extension States: Slough BA ME Berkshire SL1 3WE (GB) Designated Validation States: MA (74) Representative: UCB Intellectual Property c/o UCB Celltech (30) Priority: 16.07.2014 GB 201412659 IP Department 208 Bath Road (43) Date of publication of application: Slough, Berkshire SL1 3WE (GB) 24.05.2017 Bulletin 2017/21 (56) References cited: (73) Proprietor: UCB Biopharma SRL WO-A1-2011/025904 WO-A1-2013/085893 1070 Brussels (BE) • GOLD ET AL.: "The B Cell Antigen Receptor (72) Inventors: Activates the AKT/Glycogegn Synthase Kinase-3 • FINNEY, Helene Margaret Signalling Pathway via Phosphatydilinositol Slough 3-Kinase", J. IMMUNOLOGY, vol. 163, 1999, Berkshire SL1 3WE (GB) pages 1894-1905, XP002745175, • RAPECKI, Stephen Edward Slough Berkshire SL1 3WE (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • B Cell Checkpoints in Autoimmune Rheumatic Diseases
    REVIEWS B cell checkpoints in autoimmune rheumatic diseases Samuel J. S. Rubin1,2,3, Michelle S. Bloom1,2,3 and William H. Robinson1,2,3* Abstract | B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen- presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co- engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases. Antibody- dependent B cells are multifunctional lymphocytes that contribute that serve as precursors to and thereby give rise to acti- cell- mediated cytotoxicity to the pathogenesis of autoimmune diseases
    [Show full text]
  • Molecular Design, Optimization and Genomic Integration of Chimeric B
    bioRxiv preprint doi: https://doi.org/10.1101/516369; this version posted June 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Molecular design, optimization and genomic integration of chimeric B cell 2 receptors in murine B cells 3 4 Theresa Pesch1, Lucia Bonati1, William Kelton1, Cristina Parola1,2, Roy A Ehling1, Lucia 5 Csepregi1, Daisuke Kitamura3, Sai T ReDDy1,* 6 7 1 Department of Biosystems Science and Engineering, ETH Zürich, Basel 4058, Switzerland 8 2 Life Science Graduate School, Systems Biology, ETH Zürich, University of Zurich, Zurich 8057, 9 Switzerland 10 3 Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan 11 *To whom corresponDence shoulD be aDDresseD. Tel: +41 61 387 33 68; Email: [email protected] 12 Key worDs: B cells, synthetic antigen receptor, cellular engineering, genome eDiting, cellular 13 immunotherapy, CRISPR-Cas9 14 15 Abstract 16 Immune cell therapies baseD on the integration of synthetic antigen receptors proviDe 17 a powerful strategy for the treatment of Diverse Diseases, most notably retargeting 18 T cells engineereD to express chimeric antigen receptors (CAR) for cancer therapy. In 19 aDDition to T lymphocytes, B lymphocytes may also represent valuable immune cells 20 that can be engineereD for therapeutic purposes such as protein replacement therapy 21 or recombinant antiboDy proDuction. In this article, we report a promising concept for 22 the molecular Design, optimization anD genomic integration of a novel class of 23 synthetic antigen receptors, chimeric B cell receptors (CBCR).
    [Show full text]
  • Cd79b Expression in B Cell Chronic Lymphocytic Leukemia: Its Implication for Minimal Residual Disease Detection
    Leukemia (1999) 13, 1501–1505 1999 Stockton Press All rights reserved 0887-6924/99 $15.00 http://www.stockton-press.co.uk/leu CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection JA Garcia Vela, I Delgado, L Benito, MC Monteserin, L Garcia Alonso, N Somolinos, MA Andreu and F On˜a Department of Hematology, Hospital Universitario de Getafe, Madrid, Spain The surface expression of CD79b, using the monoclonal anti- antigen expression and antigen overexpression) in order to body (Mab) CB3–1, on B lymphocytes from normal individuals establish the applicability of immunophenotypic aberrances and patients with B cell chronic lymphocytic leukemia (CLL) for monitoring MRD as in acute leukemias with a sensitivity has been analyzed using triple-staining cells for flow cytome- −4 try. In addition, the clinical significance of CD79b expression level of 10 (one aberrant CLL cell among 10000 normal in CLL patients and its possible value for the evaluation of mini- cells). We have previously published that CD5 is overex- mal residual disease (MRD) was explored. A total of 15 periph- pressed in most CLL cases.2 This aberrantly CD5high/CD19+ eral blood (PB) samples from healthy blood donors, five bone expression was present in 90% of our CLL. Dilutional experi- marrow (BM) samples from normal donors and 40 PB samples ments showed that CD5high/CD19+ were identified at fre- from CLL untreated patients were included in the study. In −4 addition we studied the expression of CD79b in B lymphocytes quencies as low as 10 . from five CLL patients after fludarabine treatment in order to Recently, different groups have communicated that CD79b support our method.
    [Show full text]
  • Downloaded and Further Processed with the R Programming Language ( and Bioconductor ( Software
    bioRxiv preprint doi: https://doi.org/10.1101/801530; this version posted October 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. An integrated multi-omic single cell atlas to redefine human B cell memory David R. Glass,1,2,5 Albert G. Tsai,2,5 John Paul Oliveria,2,3 Felix J. Hartmann,2 Samuel C. Kimmey,2,4 Ariel A. Calderon,1,2 Luciene Borges,2 Sean C. Bendall1,2,6,* 1Immunology Graduate Program, Stanford University, Stanford, CA, 94305, USA 2Department of Pathology, Stanford University, Stanford, CA, 94305, USA 3Department of Medicine, Division of Respirology, McMaster University, Hamilton, ON, L8S4K1, Canada 4Department of Developmental Biology, Stanford, University, Stanford CA, 94305, USA 5Co-first author 6Lead Author *Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/801530; this version posted October 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Abstract: To evaluate the impact of heterogeneous B cells in health and disease, comprehensive profiling is needed at a single cell resolution. We developed a highly- multiplexed screen to quantify the co-expression of 351 surface molecules on low numbers of primary cells. We identified dozens of differentially expressed molecules and aligned their variance with B cell isotype usage, metabolism, biosynthesis activity, and signaling response.
    [Show full text]
  • Novel Immunotherapies in Lymphoid Malignancies
    REVIEWS Novel immunotherapies in lymphoid malignancies Connie Lee Batlevi1, Eri Matsuki1, Renier J. Brentjens2 and Anas Younes1 Abstract | The success of the anti‑CD20 monoclonal antibody rituximab in the treatment of lymphoid malignancies provided proof-of-principle for exploiting the immune system therapeutically. Since the FDA approval of rituximab in 1997, several novel strategies that harness the ability of T cells to target cancer cells have emerged. Reflecting on the promising clinical efficacy of these novel immunotherapy approaches, the FDA has recently granted ‘breakthrough’ designation to three novel treatments with distinct mechanisms. First, chimeric antigen receptor (CAR)-T‑cell therapy is promising for the treatment of adult and paediatric relapsed and/or refractory acute lymphoblastic leukaemia (ALL). Second, blinatumomab, a bispecific T‑cell engager (BiTE®) antibody, is now approved for the treatment of adults with Philadelphia-chromosome- negative relapsed and/or refractory B‑precursor ALL. Finally, the monoclonal antibody nivolumab, which targets the PD‑1 immune-checkpoint receptor with high affinity, is used for the treatment of Hodgkin lymphoma following treatment failure with autologous-stem-cell transplantation and brentuximab vedotin. Herein, we review the background and development of these three distinct immunotherapy platforms, address the scientific advances in understanding the mechanism of action of each therapy, and assess the current clinical knowledge of their efficacy and safety. We also discuss future strategies to improve these immunotherapies through enhanced engineering, biomarker selection, and mechanism-based combination regimens. The concept of immunotherapy for treating cancer of cell-based therapy directed at TAAs expressed on the emerged almost a century ago; the graft-versus-tumour tumour-cell surface, typically CD19 in B‑cell malignan- effect following allogeneic haematopoietic-stem-cell cies (BOX 1).
    [Show full text]
  • Immunophenotyping of Acute Leukaemias Immunophänotypisierung Akuter Leukämien
    Immunhämatologie Redaktion: G. Rothe Immunophenotyping of Acute Leukaemias Immunophänotypisierung akuter Leukämien T. Benter, R. Rätei, W.-D. Ludwig Summary: For nearly 100 years the classification of menden Einfluß gewonnen. Der Grund liegt in den blood cells and the diagnosis of leukaemia have been Fortschritten der Laser- und Computertechnologie, based on cytomorphological features after staining. aber auch an der Verfügbarkeit von Hunderten ver- Even in the era of molecular biology this is still es- schiedener monoklonaler Antikörper (moAB). die sential. Therapy of acute myeloid leukaemia (AML) is gegen eine Vielfalt von Antigenen hämatopoetischer mostly dependent on the interpretation of the morpho- Zellen gerichtet sind. logical appearance of blasts under the microscope. Cy- Dieser Übersichtsartikel fokussiert auf die Immun- tomorphology should also lead to a rational use of phänotypisierung von Patienten mit akuten Leukämien techniques like immunophenotyping, cytogenetics, flu- und zeigt den Einfluß auf die Diagnostik und Thera- orescence / situ hybridisation (FISH), and poly- pie. merase chain reaction (PCR). In the past two decades, the impact of immunophe- Schlüsselwörter: akute Leukämie: Immunophänoty- notyping by flow cytometry in the diagnosis and man- pisierung: Klassifikation von Leukämien. agement of acute leukaemia has expanded rapidly. This has been mainly attributed to significant advances in laser and computer technologies and the production of several hundred monoclonal antibodies (moAbs) to he gold standard for classifying acute myeloid a variety of antinens expressed by haematopoietic Tleukaemia (AML) has been based on morphologi- cells. cal, cytochemical, and iinmunophenotypic criteria as This review concentrates on immunophenotyping of defined by the French—American—British (FAB) sys- cells from patients with acute leukaemia and shows the tem 11-4].
    [Show full text]
  • Immunophenotypic and Functional Characterization of Human Umbilical Cord Blood Mononuclear Cells K Paloczi
    Leukemia (1999) 13, Suppl. 1, 87–89 1999 Stockton Press All rights reserved 0887-6924/99 $12.00 http://www.stockton-press.co.uk/leu Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells K Paloczi National Institute of Haematology and Immunology, Budapest, Hungary Human umbilical cord blood (CB) represents a unique source GM).7,8 Besides the different culture systems immunofluo- of transplantable hematopoietic progenitor cells. Potential rescence and flow cytometry can be regarded as a reliable advantages of using CB relate to the high number and quality of hematopoietic stem and progenitor cells present in the circu- and rapid method for detection of early stem/progenitor cells. lation at birth and to the relative immune immaturity of the new- The CD34 antigen is of particular interest because it represents born immune cells. Discussed in this review are: (a) Quantity the only cell-surface antigen identified by monoclonal anti- and quality of immature hematopoietic stem and progenitor bodies (MoAb), whose expression within the hematopoietic cells from cord blood; (b) Immune cells in cord blood including system is restricted to primitive progenitor cells of all the number of B- and T-lymphocytes, as well as natural killer 9 cells and characterization of their functional capacities; (c) The lineages. 1,2 need of an international CB transplantation registry and the According to the previous reports, cord blood represents availability of cord blood banks. Although still in its infancy, a rich source of hematopoietic stem/progenitor cells, but human CB progenitor cells hold considerable potential for in CD34+ cell enumeration was not reported for these studies.
    [Show full text]
  • BTK Inhibitors in Chronic Lymphocytic Leukemia: a Glimpse to the Future
    Oncogene (2015) 34, 2426–2436 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc REVIEW BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future M Spaargaren1,2, MFM de Rooij1, AP Kater2,3 and E Eldering2,4 The treatment of chronic lymphocytic leukemia (CLL) with inhibitors targeting B cell receptor signaling and other survival mechanisms holds great promise. Especially the early clinical success of Ibrutinib, an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), has received widespread attention. In this review we will focus on the fundamental and clinical aspects of BTK inhibitors in CLL, with emphasis on Ibrutinib as the best studied of this class of drugs. Furthermore, we summarize recent laboratory as well as clinical findings relating to the first cases of Ibrutinib resistance. Finally, we address combination strategies with Ibrutinib, and attempt to extrapolate its current status to the near future in the clinic. Oncogene (2015) 34, 2426–2436; doi:10.1038/onc.2014.181; published online 23 June 2014 INTRODUCTION TO CHRONIC LYMPHOCYTIC LEUKEMIA Healthy B cells become activated upon antigen ligation to the Chronic lymphocytic leukemia (CLL), the most common adult B cell receptor (BCR), resulting in proliferation and differentiation. leukemia in western countries, is a neoplastic disease of This can be further enhanced by cytokine stimulation and co- monoclonal CD5+ B cells, which accumulate in blood, marrow stimulation. The various signals from the microenvironment and secondary lymphoid tissues. The median age at diagnosis lies together orchestrate the activation of B cells and likewise of CLL between 65 and 70 years.
    [Show full text]
  • Introduction to Flow Cytometry
    Introduction to Flow Cytometry Jesse Manuel Jaso, M.D. 7/28/2015 Flow Cytometry • Flow cytometry is the measurement of single cells as they pass single file through a beam of light in a fluid stream • Cells are “flowing” through the instrument (flow cell) • More control over which cells are being examined (cell sorting) • Generate data for only the cells you are interested in Flow Cytometric Immunophenotyping • Characterization of a cell or group of cells by the presence or absence of certain antigens on their surface or in their cytoplasm • Pre-described immunophenotypes can be used to aid in the diagnosis of hematopoietic neoplasms • Pattern recognition + Right context • Majority of the time, this is what we are talking about when we say “flow cytometry” Figure 2 T LYMPHOMAS AND ANGIOIMMUNOBLASTIC CD5+/CD10+/CD3+/CD4+ MARGINAL ZONE CD19, CD20, CD22, CD79, sIg, FMC7, bcl-2, CD23+ (CD5, CD10, CD43, bcl-6 neg) SEZARY CD3, CD2, CD5, CD4, CD7+/-(CD8 neg) NODAL MALT LARGE CELLS ANAPLASTIC CD2, CD4, CD3+, CD30 CLL CD19, CD20, CD43,CD23, sIg+/-, CD5 (CD79 CD10, CD22, PERIPHERAL CD2, CD3, CD5, CD4 FMC7 neg) ANGIOCENTRIC CD2, CD5, CD4 ou CD8, CD56 HCL CD19, CD20, CD22, sIg++, CD11c, CD25, CD103, CD123 (CD5, CD10, CD23 neg) INTESTINAL CD3, CD7, CD103 ATLL CD3, CD4, CD25, CD45RO, CD7neg MANTLE ZONE CD19, CD20, CD22, CD79, FMC7, sIg, bcl-1, CD5, CD43, (CD10, CD23 neg) BURKITT CD19, CD20, CD22, FOLLICULAR CD19, CD20, CD22, sIg+, CD79, CD79, sIg, CD10, DR, bcl-6 CD10, bcl-2 (CD5, CD23, Tdt neg) (CD5, CD23, CD43 neg) WALDENSTROM CD19, CD20+, CD22, CD79
    [Show full text]
  • Human Antibody Array, 1000 Targets Cat.No: WHA-R381
    Human Antibody Array, 1000 Targets Cat.No: WHA-R381 DESCRIPTION Description Human Antibody Array, Membrane (# WHA-R381). Detects 1000 Human Proteins. Suitable for Cell culture supernatants. PRODUCT INFORMATION Targets 11b-HSD1, 2B4, 4-1BB, 6Ckine, A1BG, A2M, ABL1, ACE, ACE-2, ACK1, ACPP, ACTH, Activin A, Activin B, Activin C, Activin RIA / ALK-2, Activin RIB / ALK-4, Activin RII A/B, Activin RIIA, ADAM-9, ADAMTS-1, ADAMTS-10, ADAMTS-13, ADAMTS-15, ADAMTS-17, ADAMTS-18, ADAMTS-19, ADAMTS-4 , ADAMTS-5, ADAMTS-L2, Adiponectin / Acrp30, Adipsin, Afamin, AFP, AgRP, ALBUMIN, ALCAM, Aldolase A, Aldolase B, Aldolase C, ALK, Alpha 1 AG, Alpha 1 Microglobulin, Alpha Lactalbumin, ALPP, AMICA, AMPKa1, Amylin, Angiogenin, Angiopoietin-1, Angiopoietin-2, Angiopoietin-4, Angiopoietin-like 1, Angiopoietin-like 2, Angiopoietin-like Factor, Angiostatin, ANGPTL3, ANGPTL4, Annexin A7, APC, APCS, Apelin, Apex1, APJ, APN, ApoA1, ApoA2, ApoA4, ApoB, ApoB100, ApoC1, ApoC2, ApoC3, ApoD, ApoE, ApoE3, ApoH, ApoM, APP, APRIL, AR (Amphiregulin), Artemin, ASPH, Attractin, Axl, B3GNT1, B7-1 /CD80, BACE-1, BAF57, BAFF, BAFF R / TNFRSF13C, BAI-1, bax, BCAM, BCMA / TNFRSF17, BD- 1, BDNF, Beta 2M, Beta Defensin 4, Beta IG-H3, beta-Catenin, beta-NGF, Biglycan, BIK, BLAME, BLC / BCA-1 / CXCL13, BMP-15, BMP-2, BMP-3, BMP-3b / GDF-10, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMPR-IA / ALK-3, BMPR-IB / ALK- 6, BMPR-II, BMX, BNIP2, BNP, BTC, Btk, C2, C3a, C5/C5a, C7, C8B, C9, CA125, CA15-3, CA19-9, CA9, Cadherin-13, Calbindin, Calbindin D, Calcitonin, Calreticulin, Calsyntenin-1,
    [Show full text]
  • Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's
    Published OnlineFirst March 3, 2009; DOI: 10.1158/0008-5472.CAN-08-2250 Research Article Antibody-Drug Conjugates for the Treatment of Non–Hodgkin’s Lymphoma: Target and Linker-Drug Selection Andrew G. Polson, Jill Calemine-Fenaux, Pamela Chan, Wesley Chang, Erin Christensen, Suzanna Clark, Frederic J. de Sauvage, Dan Eaton, Kristi Elkins, J. Michael Elliott, Gretchen Frantz, Reina N. Fuji, Alane Gray, Kristin Harden, Gladys S. Ingle, Noelyn M. Kljavin, Hartmut Koeppen, Christopher Nelson, Saileta Prabhu, Helga Raab, Sarajane Ross, Dion S. Slaga, Jean-Philippe Stephan, Suzie J. Scales, Susan D. Spencer, Richard Vandlen, Bernd Wranik, Shang-Fan Yu, Bing Zheng, and Allen Ebens Genentech, Inc., South San Francisco, California Abstract a specific microenvironment found in or on the target tumor cell. Antibody-drug conjugates (ADC), potent cytotoxic drugs Examples include linkers that are cleaved by acidic conditions, covalently linked to antibodies via chemical linkers, provide reducing conditions, or proteases (4–6). Another option is to have a means to increase the effectiveness of chemotherapy by stable linkers that are not cleaved, but rather, coupled to antibodies targeting the drug to neoplastic cells while reducing side against tumor antigens that are internalized and then degraded, effects. Here, we systematically examine the potential targets releasing the drug attached to the conjugating amino acid within and linker-drug combinations that could provide an optimal cells (7, 8). Thus, the active metabolite(s) and amounts of active drug released should be substantially different for the cleavable ADC for the treatment for non–Hodgkin’s lymphoma. We identified seven antigens (CD19, CD20, CD21, CD22, CD72, linker ADC and this could affect the safety and efficacy of the CD79b, and CD180) for potential treatment of non–Hodgkin’s ADCs.
    [Show full text]